{
  "drugid": "RxNorm:301542",
  "drugname": "rosuvastatin",
  "guidelinename": "SLCO1B1, ABCG2, CYP2C9, and Statins",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
  "guidelinepharmgkbids": [
    "PA166105005",
    "PA166262221",
    "PA166262241",
    "PA166262261",
    "PA166262281",
    "PA166262321",
    "PA166262341"
  ],
  "citations": [
    {
      "pmid": "22617227",
      "title": "The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy",
      "authors": [
        "Wilke R A",
        "Ramsey L B",
        "Johnson S G",
        "Maxwell W D",
        "McLeod H L",
        "Voora D",
        "Krauss R M",
        "Roden D M",
        "Feng Q",
        "Cooper-Dehoff R M",
        "Gong L",
        "Klein T E",
        "Wadelius M",
        "Niemi M"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2012
    },
    {
      "pmid": "24918167",
      "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update",
      "authors": [
        "Ramsey Laura B",
        "Johnson Samuel G",
        "Caudle Kelly E",
        "Haidar Cyrine E",
        "Voora Deepak",
        "Wilke Russell A",
        "Maxwell Whitney D",
        "McLeod Howard L",
        "Krauss Ronald M",
        "Roden Dan M",
        "Feng Qiping",
        "Cooper-DeHoff Rhonda M",
        "Gong Li",
        "Klein Teri E",
        "Wadelius Mia",
        "Niemi Mikko"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2014
    },
    {
      "pmid": "35152405",
      "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.",
      "authors": [
        "Cooper-DeHoff Rhonda M",
        "Niemi Mikko",
        "Ramsey Laura B",
        "Luzum Jasmine A",
        "Tarkiainen E Katriina",
        "Straka Robert J",
        "Gong Li",
        "Tuteja Sony",
        "Wilke Russell A",
        "Wadelius Mia",
        "Larson Eric A",
        "Roden Dan M",
        "Klein Teri E",
        "Yee Sook Wah",
        "Krauss Ronald M",
        "Turner Richard M",
        "Palaniappan Latha",
        "Gaedigk Andrea",
        "Giacomini Kathleen M",
        "Caudle Kelly E",
        "Voora Deepak"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022
    }
  ],
  "recommendations": [
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "No Result"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "No Result"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Decreased Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "n/a",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "No Result",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "n/a",
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "No Result",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "n/a",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "n/a",
      "classification": "n/a",
      "phenotypes": {
        "ABCG2": "No Result",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "n/a",
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "No Result",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "n/a",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). ABCG2 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "No Result",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "n/a",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "No Result",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "No Result",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 genotype result is not available.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "No Result"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "No Result"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose > 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Typical myopathy risk and rosuvastatin exposure",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.",
      "classification": "Strong",
      "phenotypes": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Normal Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "No Result"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "No Result"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1": "Typical myopathy risk and statin exposure"
      },
      "drugrecommendation": "Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "ABCG2": "Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects",
        "SLCO1B1": "Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg."
      },
      "drugrecommendation": "Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "ABCG2": "Poor Function",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "ABCG2",
    "SLCO1B1"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.21.2",
  "source": "CPIC"
}